Meeting
2018 Gastrointestinal Cancers Symposium
A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
Authors
Yoanna S Pumpalova
Stanford University, Palo Alto, CA
Yoanna S Pumpalova , Margaret M. Kozak , Rie von Eyben , George A. Fisher Jr., Pamela L. Kunz , Daniel Tandel Chang , Sigurdis Haraldsdottir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 710)
DOI
10.1200/JCO.2018.36.4_suppl.710
Abstract #
710
Poster Bd #
G23
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A comparison between 5-fluorouracil/mitomycin (FM) and capecitabine/mitomycin (CM) in combination with radiation (RT) for squamous cell carcinoma (SCC) of the anal canal.
First Author: Dante D.C. Wan
Poster
2012 Gastrointestinal Cancers Symposium
Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.
First Author: Melissa Pulfer Mitchell
Poster
2017 Gastrointestinal Cancers Symposium
Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.
First Author: Irene S. Yu
Poster
2017 Gastrointestinal Cancers Symposium
Long-standing Crohn’s disease and its implication on anal squamous cell cancer management.
First Author: Sara Moncrief